Inhibrx Biosciences, Inc.
INBXInhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates using proprietary modular protein engineering platforms.
Earnings
Next report
Nov 13, 2026 (in 2 months)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates using proprietary modular protein engineering platforms. The company specializes in creating multivalent protein therapeutics designed to optimize agonist functions for challenging and validated biological targets. Their primary mission is to address life-threatening conditions through a pipeline of differentiated oncology treatments.
A clinical-stage innovator utilizing proprietary protein engineering platforms to develop high-valency agonists for validated oncology targets.
FAQ
- What is Inhibrx Biosciences, Inc.'s market cap?
- Inhibrx Biosciences, Inc. (INBX) has a market capitalization of $1.8B and trades on NASDAQ.
- What is Inhibrx Biosciences, Inc.'s revenue and profitability?
- Inhibrx Biosciences, Inc. generated $1.3M in trailing twelve-month revenue with a net loss of $138.2M, representing a net margin of -10773.5%, with free cash flow of -$131.9M. These figures are based on the Q2 2026 filing.
- Who are Inhibrx Biosciences, Inc.'s competitors?
- Inhibrx Biosciences, Inc.'s key competitors include Genentech, Inc., Gilead Sciences, Inc., Merck & Co., and others. These companies compete in similar markets and product categories.
- Who does Inhibrx Biosciences, Inc. partner with?
- Inhibrx Biosciences, Inc.'s notable partners include Sanofi S.A..
- Where is Inhibrx Biosciences, Inc. headquartered?
- Inhibrx Biosciences, Inc. is headquartered in United States of America and employs approximately 172 people. It has been publicly traded since 2024.
